HOME >> BIOLOGY >> NEWS
24-Wk data from CONTEXT trial comparing GW433908/ritonavir QD & BID to Lopinavir/ritonavir BID

regimen over a period of 48 weeks. Results from the SOLO trial were presented in November 2002 at the 6th International Congress on Drug Therapy in HIV Infection in Glasgow, United Kingdom.

NEAT was a phase III, randomized, open-label, parallel-group 48-week study that compared 908 BID and nelfinavir BID, both in combination with ABC and 3TC in 249 antiretroviral therapy-nave patients. The primary endpoint of the NEAT study was the proportion of subjects with vRNA <400 c/mL at 24 and 48 weeks. Interim 24-week data from NEAT were presented in September at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICACC) in San Diego, and 48-week data are being presented here today.

Once approved, GSK will market 908 and GSK and Vertex will co-promote it in the United States and key markets in Europe.

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies and an industry leader in HIV research and therapies. The company is engaged in basic research programs designed to investigate new targets to treat HIV.

This press release may contain forward-looking statements, including that 48-week interim analysis of the NEAT and SOLO studies in GlaxoSmithKline's pivotal program for 908 is indicative of a promising clinical and commercial outlook for 908, once approved. While management makes its best efforts to be accurate in making forward-looking statements, such statements are subject to risks and uncertainties that could cause Vertex's actual results to vary materially. These risks and uncertainties include, among other things, the risk that approval will be delayed or will not be obtained, that 908 will not be commercially successful, and those other risks listed under Risk Factors in Vertex's form 10-K filed with the Securities and Exchange Commission on April 1, 2002.


'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
14-Feb-2003


Page: 1 2 3 4

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 23, 2017 /PRNewswire/ - The Fight Against Cancer Innovation ... (OICR) are pleased to report that Fusion Pharmaceuticals Inc. ... Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as ... HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well ... ...
(Date:2/23/2017)... -- In Atlanta, it seems everyone has a chance to express ... an expressive and dynamic community unlike any other. The businesses ... it. With their newest salon in ... carry on that tradition with a unique, fresh approach to ... is the newest of 13 nationwide locations, each of them ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
Breaking Biology Technology:
Cached News: